Letrozole Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 2.5 mg
Reference Brands: Femara® (US & EU)
Category:
Oncology Cancer Care
Letrozole (brand name Femara®) is an oral aromatase inhibitor used to treat hormone receptor-positive breast cancer in postmenopausal women. Approved in the US and EU, it comes in a 2.5 mg tablet. Widely available through B2B pharma channels, Letrozole is GMP-compliant and reliably supplied to hospitals and oncology centers at competitive prices
Letrozole is available in Tablets
and strengths such as 2.5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Letrozole is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Letrozole can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Letrozole, sold under the brand name Femara®, is a highly effective aromatase inhibitor used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Approved in both the US and EU, Letrozole is available in 2.5 mg oral tablets and is widely prescribed for early and advanced-stage breast cancer. As a key hormonal therapy, Letrozole is sourced globally by B2B pharmaceutical wholesalers, hospitals, and oncology clinics. With GMP-compliant manufacturing and reliable supply chains, Letrozole offers consistent quality and competitive pricing in the European and American markets, supporting cancer care with trusted pharmaceutical standards.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing